



# EWOC-1



## Elderly Women Ovarian Cancer

Multicenter, randomized trial of carboplatin +/- paclitaxel in vulnerable elderly patients with stage IIB-IV advanced ovarian cancer

## First ENGOT-GCIG international study of elderly patients in Ovarian Cancer

### ENGOT OV-23

#### Participating Groups

GINECO, AGO, MITO, ANZGOG, Canada, ICORG, GOTIC, NSGO



# EWOC-1 Flow chart

**PRIMARY ENDPOINT**  
Rate of success to deliver 6 courses of chemotherapy without progression or unacceptable toxicity of 3 different regimens in vulnerable elderly patients

**Patient identification**

70 years old  
Stage III-IV ovarian cancer  
Initial diagnosis

YES

**GVS screening**  
score ADL < 6  
score IADL < 25  
score HADS > 14  
albuminemia < 35g/L  
lymphopenia < 1G/L  
  
→ Vulnerable patient if GVS ≥ 3

NO

**Registry**  
Chemotherapy per investigator choice

YES

Inclusion and exclusion criteria respect?

NO

YES

**Ewoc-1 randomization**  
240 patients


Intervall debulking is allowed

**Arm A**  
carboplatin AUC 5 + paclitaxel  
175mg/m<sup>2</sup> q21  
X 6 cycles

**Arm B**  
carboplatin AUC 5-6  
q21  
X 6 cycles

**Arm C**  
carboplatin AUC 2 + paclitaxel  
60 mg/m<sup>2</sup> weekly q28 (d1, d8, d15) x 6 cycles

# EWOC-1 Recruitment



# Next steps

## ▶ International opening



**MITO**

**NSGO**

**ICORG**

**AGO**



**Montreal Consortium**

**JGOG- GOTIC**

**ANZGOG**

- MITO : Open for recruitment
- NSGO, ICORG and Montreal in submission process